No Data
No Data
Cybrid Technologies Inc.: Shareholder Silver Splendor Investment intends to reduce its shareholding by no more than 3%; Xiangxue Pharmaceutical: The company and the controlling shareholder received a notice of filing from the China Securities Regulatory C
Cybrid Technologies Inc. shareholders Silver Glory Investment intend to reduce their shareholding by no more than 3%; Shareholders of Pava Co., Ltd., Huayi Xinyuan No.1, Huayi Xinyuan No.2, Huayi Xinyuan No.3 intend to collectively reduce their shareholding by no more than 3%; China XD Electric shareholder General Electric Singapore Company intends to reduce by no more than 3%; Lattice Power shareholders Junlian Chengye, Junlian Huicheng intend to reduce their shareholding by no more than 2%; Tibet Urban Development and Investment's 0.132 billion restricted shares will be released on October 8; Zhongfu Information Inc.'s 34.8516 million restricted shares will be released on October 8; Zhongke Magnetic Technology Co., Ltd.'s 5.2688 million restricted shares will be released on October 8; Xiangxue Pharmaceutical stated that the company and the actual controller because of
Xiangxue Pharmaceutical Co.,Ltd. (SZSE:300147) Looks Inexpensive After Falling 39% But Perhaps Not Attractive Enough
While Xiangxue PharmaceuticalLtd (SZSE:300147) Shareholders Have Made 28% in 1 Year, Increasing Losses Might Now Be Front of Mind as Stock Sheds 9.2% This Week
Xiangxue Pharmaceuticals: Semi-Annual Report 2024
Xiangxue Pharmaceuticals: 2024 Semi-Annual Report Summary
Xiangxue Pharmaceutical (300147.SZ) released its performance for the first half of the year, with a net loss of 0.135 billion yuan, and the loss expanded.
Xiangxue Pharmaceutical (300147.SZ) released its 2024 interim report, with revenue of 1.097 billion yuan...
Xiangxue Pharmaceutical Co.,Ltd.'s (SZSE:300147) 29% Dip In Price Shows Sentiment Is Matching RevenuesNo Data
No Data
